Bromfenac
- Generic Name
- Bromfenac
- Brand Names
- Bromday, Bromsite, Prolensa, Xibrom, Yellox
- Drug Type
- Small Molecule
- Chemical Formula
- C15H12BrNO3
- CAS Number
- 91714-94-2
- Unique Ingredient Identifier
- 864P0921DW
- Background
Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use. Ophthalmic NSAIDs are becoming a cornerstone for the management of ocular pain and inflammation. Their well-characterized anti-inflammatory activity, analgesic property, and established safety record have also made NSAIDs an important tool for optimizing surgical outcomes. Non-ophthalmic formulations of bromfenac were withdrawn in the US in 1998 due to cases of severe liver toxicity.
- Indication
For the treatment of postoperative inflammation in patients who have undergone cataract extraction.
- Associated Conditions
- Eye Pain, Ocular Inflammation
PGE2 Levels in Patient Treated With NSAIDs
- Conditions
- Ocular Inflammation
- Interventions
- First Posted Date
- 2018-07-24
- Last Posted Date
- 2018-07-24
- Lead Sponsor
- University of Trieste
- Target Recruit Count
- 104
- Registration Number
- NCT03597867
- Locations
- 🇮🇹
Eye Clinic, Departement of Medical Surgical Sciences and Health, University of Trieste, Trieste, TS, Italy
Prophylactic Treatment: Lessdrops™ vs Standard Drops Regimen
- Conditions
- Cataract
- Interventions
- First Posted Date
- 2018-07-06
- Last Posted Date
- 2022-06-10
- Lead Sponsor
- Carolina Eyecare Physicians, LLC
- Target Recruit Count
- 35
- Registration Number
- NCT03578276
- Locations
- 🇺🇸
Carolina Eyecare Physicians, LLC, Mount Pleasant, South Carolina, United States
Efficacy and Safety of PRO-155 on Inflammation of the Conjunctival Surface in Subjects With Grade I-III Pterygium vs Placebo.
- Conditions
- PterygiumOcular PainOcular InflammationPost-surgical Inflammation
- Interventions
- Other: Placebo
- First Posted Date
- 2018-05-11
- Last Posted Date
- 2019-11-20
- Lead Sponsor
- Laboratorios Sophia S.A de C.V.
- Target Recruit Count
- 166
- Registration Number
- NCT03521791
- Locations
- 🇲🇽
Consultorio PRivado Miguel Angel Villanueva, Ciudad de México, Mexico
🇲🇽catarata y glaucoma de occidente S.A de C.V., Guadalajara, Jalisco, Mexico
🇲🇽Novam y Vita, Guadalajara, Jalisco, Mexico
Bromfenac Versus Dexamethasone After Cataract Surgery
- Conditions
- Inflammation Eye
- Interventions
- First Posted Date
- 2017-10-23
- Last Posted Date
- 2019-06-03
- Lead Sponsor
- Arcispedale Santa Maria Nuova-IRCCS
- Target Recruit Count
- 76
- Registration Number
- NCT03317847
- Locations
- 🇮🇹
Arcispedale Santa Maria Nuova IRCSS - Ophthalmology, Reggio Emilia, RE, Italy
Pseudophakic Cystoid Macular Lesions After Uncomplicated Standard Phacoemulsification
- Conditions
- Pseudophakic Cystoid Macular Lesions After Uncomplicated Standard Phacoemulsification
- Interventions
- First Posted Date
- 2017-04-10
- Last Posted Date
- 2017-04-10
- Lead Sponsor
- Kyungpook National University Hospital
- Target Recruit Count
- 316
- Registration Number
- NCT03106402
Topical 0.1% Bromfenac Sodium and Prostaglandin E2 Inhibition in Cataract Surgery
- Conditions
- Cataract
- Interventions
- Procedure: femtosecond laser cataract surgery
- First Posted Date
- 2016-02-12
- Last Posted Date
- 2016-02-12
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 60
- Registration Number
- NCT02681679
- Locations
- 🇨🇳
Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, Guangdong, China
NSAIDs and PGE2 Levels in Vitrectomy Patients
- Conditions
- Vitreous Inflammation
- Interventions
- First Posted Date
- 2015-02-12
- Last Posted Date
- 2015-02-12
- Lead Sponsor
- Università degli Studi di Brescia
- Target Recruit Count
- 70
- Registration Number
- NCT02361645
Bromfenac to Reduce Inflammation in Patients With Pseudoexfoliation Syndrome After Cataract Surgery
- Conditions
- Pseudoexfoliation SyndromeCataract
- Interventions
- Drug: Dexamethasone+Tobramycin eye drop
- First Posted Date
- 2014-05-13
- Last Posted Date
- 2014-10-29
- Lead Sponsor
- Arcispedale Santa Maria Nuova-IRCCS
- Target Recruit Count
- 62
- Registration Number
- NCT02137161
- Locations
- 🇮🇹
Arcispedale Santa Maria Nuova IRCSS - Ophthalmology, Reggio Emilia, RE, Italy
Prolensa (Bromfenac) 0.07% QD vs. Ilevro (Nepafenac) 0.3% QD for Treatment of Ocular Inflammation Post Cataract Surgery
- Conditions
- Retinal EdemaInflammationCataract
- Interventions
- First Posted Date
- 2013-05-07
- Last Posted Date
- 2018-11-14
- Lead Sponsor
- Melissa Toyos
- Target Recruit Count
- 50
- Registration Number
- NCT01847638
- Locations
- 🇺🇸
Toyos Clinic, Nashville, Tennessee, United States
Comparison Study of ISV-303 to Durasite Vehicle in Cataract Surgery Subjects
- First Posted Date
- 2013-03-11
- Last Posted Date
- 2021-11-19
- Lead Sponsor
- Sun Pharmaceutical Industries Limited
- Target Recruit Count
- 268
- Registration Number
- NCT01808547
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.